The genetic and biochemical basis of human leading strand synthesis

A Alessandro Agnarelli L Lauryn Buckley-Benbow M Meryem Ozgencil M Melanie Lad (Cancer Research Horizons, Joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre) K Khamal Kwesi Ampah A Alex Kalinka O Ondrej Belan S Sarah Maslen M Mark J. Skehel D David Walter (Cancer Research Horizons, Joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre) M Matthew Day R Roberto Bellelli

Abstract

Abstract The maintenance of genome stability requires efficient leading strand synthesis by DNA Polymerase Epsilon (Polε). By performing CRISPR genetic screens in cells lacking the POLE4 subunit of Polε we define a genetic map of the factors required to support Polε function in the absence of its accessory subunits. A set of genes involved in iron metabolism emerge as required to sustain Iron Sulphur Cluster (ISC)-dependent Polε activity. We then dissect a synthetic lethal interaction between POLE3-POLE4 and the CHTF18-RFC2/5 complex. By combining cell biology, structural modelling and biochemistry, we define the existence of two tiers of regulation of Polε processivity: leading strand-specific loading of PCNA by CHTF18-RFC2/5 and “gripping” of newly synthesised dsDNA by POLE3-POLE4. The combined loss of these functions is incompatible with leading strand synthesis and viability. In summary, we describe the biochemical basis of human leading strand synthesis and the consequence of its dysfunction in genome stability.

Article Details

Volume / Issue Vol. 17, Issue 1
Published December 04, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (12)

A

Alessandro Agnarelli

L

Lauryn Buckley-Benbow

M

Meryem Ozgencil

M

Melanie Lad

Cancer Research Horizons, Joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre

K

Khamal Kwesi Ampah

A

Alex Kalinka

O

Ondrej Belan

S

Sarah Maslen

M

Mark J. Skehel

D

David Walter

Cancer Research Horizons, Joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre

M

Matthew Day

R

Roberto Bellelli